BrainAurora Medical Technology Limited will convene its 2026 annual general meeting (AGM) online on 18 June at 10:00 a.m. Key resolutions include fresh share mandates, director re-elections and auditor re-appointment.

Mandate proposals • Issuance mandate: Directors seek authority to allot, issue or transfer out of treasury up to 20% of the company’s issued share capital (excluding any treasury shares) as at the AGM date, equal to a maximum 271.66 million shares based on the current 1.36 billion shares outstanding. • Buy-back mandate: The Board also requests power to repurchase up to 10% of issued shares, or 135.83 million shares, during the mandate period. • Extension mandate: Any shares repurchased under the buy-back mandate may be added to the issuance limit, potentially expanding the aggregate shares that can be issued.

Board composition Five directors are standing for re-election: non-executive directors Deng Feng, Yang Fan and Wang Jingbo, and independent non-executive directors Duan Tao and Tu Lei. Each has a three-year appointment term upon re-election.

Auditor Deloitte Touche Tohmatsu is nominated for re-appointment. The forecast audit fee for the 2026 financial year is expected to range between RMB1.60 million and RMB2.00 million, broadly in line with the prior year.

Key timetable • Last day for share transfers: 12 June 2026 (4:30 p.m.) • Register closed: 15 June – 18 June 2026 (both days inclusive) • Record date for AGM voting: 18 June 2026 Shareholders may attend and vote electronically via the Vistra eVoting Portal or submit proxy forms no later than 10:00 a.m. on 16 June 2026.

Voting arrangements All resolutions will be decided by poll. Treasury shares, if any, will carry no voting rights.

If approved, the new mandates will remain valid until the earlier of the next AGM, the statutory deadline for holding that meeting, or any earlier revocation by shareholders.